Biochips enable the accurate, rapid, and high-throughput detection of DNA, RNA, polypeptides, proteins, cells, tissues, and other biological components, with great advantages in disease screening and early diagnosis.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Gene Solutions and Topgen Biomedical Technology said Thursday that they have entered a partnership under which Shaoxing, China-based Topgen will offer various genomic tests developed by Gene Solutions for cancer early detection and monitoring.

Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced a first closing of $27 million (circa £22 million) in its Series E financing round. The fundraise was led by Ventura Capital, joined by Aviva Ventures, Horizons Ventures, and other existing investors. The close also saw completion of the investment from the Gates Foundation.

Mirxes, a leading RNA technology company specializing in early cancer detection and precision medicine, today announced a US$40 million structured financing transaction with CBC Group’s R-Bridge Healthcare Fund (“R-Bridge”). This partnership will provide critical support for Mirxes’ ambitious growth and expansion into key global markets.

Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology, today announced a new collaboration with UK Biobank to create the world’s first comprehensive, large-scale epigenetic dataset. The project will utilise Oxford Nanopore’s information-rich DNA/RNA sequencing technology to map the epigenome of 50,000 participant samples to unlock crucial insights into disease mechanisms, with the aim of improving patient outcomes. This publicly available data will serve as a unique resource for the scientific community, bringing new opportunities to advance our understanding of genomics.

Prenetics Global Limited (NASDAQ: PRE), a leading health sciences company, today announced that Tencent has made a strategic US$30 million investment in Insighta, a Hong Kong-based early cancer detection company. This investment values Insighta at US$200 million and underscores Tencent’s endeavor to advancing AI-powered innovations in healthcare.

Agappe Diagnostics Ltd., India’s leading In Vitro Diagnostics (IVD) manufacturer, has announced its partnership with Fujirebio Holdings Inc. of Japan to unveil the first “Make in India” In-Vitro Biomarkers using CLEIA (Chemiluminescent Enzyme Immunoassay) technology.

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the peer-reviewed publication of an analytical validation study of its EsoGuard® Esophageal DNA test for the diagnosis of esophageal precancer (Barrett's Esophagus or BE) and esophageal adenocarcinoma (EAC) on samples collected non-endoscopically using Lucid's EsoCheck® Esophageal Cell Collection Device. The manuscript, entitled Analytical Validation of a DNA Methylation Biomarker Test for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma from Samples Collected Using EsoCheck®, a Non-Endoscopic Esophageal Cell Collection Device, has been published in the peer-reviewed journal Diagnostics, and is currently available via open access online.

Gene Solutions announced Monday that it will partner with the National Cancer Society of Malaysia (NCSM) to expand awareness and enable access to multi-cancer early detection (MCED) testing.